{"canonical":"https://abierto.us/vendors/selux-diagnostics-inc-d258v8mnlga5","key":"D258V8MNLGA5","name":"SELUX DIAGNOSTICS, INC.","uei":"D258V8MNLGA5","city":"WATERTOWN","state":"MA","awards":1,"obligated":"-11706.15","notices_won":0,"top_agency_name":"Office of Assistant Secretary for Preparedness and Response","top_naics":"541714","cage":"7BEN0","parent_name":"SELUX DIAGNOSTICS, INC.","also_known_as":[],"country":"USA","actions":4,"first_action":"2024-04-25","last_action":"2026-05-13","breakdowns":{"naics":[{"key":"541714","name":null,"awards":1,"obligated":"-11706.15"}],"places":[{"key":"MA","name":null,"awards":1,"obligated":"-11706.15"}],"agencies":[{"key":"7505","name":"Office of Assistant Secretary for Preparedness and Response","awards":1,"obligated":"-11706.15"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":1,"obligated":"-11706.15"}],"competition":[{"key":"FULL AND OPEN COMPETITION","name":null,"awards":1,"obligated":"-11706.15"}],"product_service_codes":[{"key":"6505","name":null,"awards":1,"obligated":"-11706.15"}]},"awards_list":[{"award_key":"CONT_AWD_75A50118C00013_7505_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75A50118C00013_7505_-NONE-_-NONE-/","piid":"75A50118C00013","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"D258V8MNLGA5","recipient_name":"SELUX DIAGNOSTICS, INC.","recipient_uei":"D258V8MNLGA5","recipient_cage":"7BEN0","recipient_city":"WATERTOWN","recipient_state":"MA","sub_name":"Office of Assistant Secretary for Preparedness and Response","office_name":"BARDA - ASPR / DAAPPO / BARDA DCMA","office_key":"o-75A501","first_action_date":"2024-04-25","last_action_date":"2026-05-13","actions":4,"obligated":"-11706.15","current_total_value":"62626466.75","potential_total_value":"70578260.68","naics":"541714","psc":"6505","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":1,"description":"EO14042 THE PURPOSE OF THIS CONTRACT IS TO DEVELOP A RAPID ID AND PHENOTYPIC ANTIBIOTIC SUSCEPTIBILITY TESTING (AST) PLATFORM TO ACCEPT DIRECT PATIENT SAMPLES. MODIFICATION P00009 IS TO UPDATE SECTION J - STATEMENT OF WORK TO REMOVE SECTION 3.2 G1 MD","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":1,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}